Amakem appoints Kieran Rooney as Vice President, Business Development

Belgian firm specialises in the development of treatments for ophthalmology

Amakem, a Belgian clinical stage ophthalmology company, has appointed Kieran Rooney as Vice President of Business Development.

Rooney brings to Amakem more than 25 years of experience in the biotechnology and pharmaceutical industries and a track record in business development, commercial management and strategic consulting. As Founder and Managing Director of Halo BioConsulting, he has worked extensively in the ophthalmology space, supporting companies in both Europe and the US on transactions and commercial strategy.

Rooney was previously a consultant to the UK Government, focusing on the provision of commercial consulting, business development and global dealmaking services to UK-based life sciences companies. Prior to this, he held Business Development Director roles at companies including Smith & Nephew, F2G, Pharsight Corporation, and MDS Pharma Services.

Amakem’s leading candidate, AMA0076, is for glaucoma and entered Phase IIa development late last year. The company is also working to apply the Localised Drug Action approach to a range of other eye diseases.

You may also like

Research & Development

Amakem secures €1.4m grant

To apply its Localised Drug Action Technology in Inflammatory Bowel Diseases (IBD)
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Subscribe now